About
Clinical development of a prophylactic vaccine for prevention of visceral / post kala azar dermal leishmaniasis
PREV_PKDL is a collaborative project funded by the European & Developing Countries Clinical Trials Partnership (EDCTP2) Programme supported by the European Union. The project is the joint effort of leading European and African experts with proven track records in research and development of products against leishmaniasis.
TARGET DISEASE: Visceral Leishmaniasis & Post kala azar dermal Leishmaniasis
TIMELINE: 01 April 2018 to 31 December 2025
COORDINATOR: Flavia D'Alessio, European Vaccine Initiative, Germany
FUNDER: EDCTP2
FUNDING: € 8 Mio
1. SHIGETECVAX:
Contact details
Please sign in to see contact details.
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views
- Comments 0